BNET Industries
Market Cap:$168.5K
Last Fiscal Year Sales:$1.0M
- Public
- CA
Dow Jones Description
We market and distribute bioscience products designed to enhance the well-being and health of individuals. Bioscience products are natural compounds that have health promoting, disease preventing or medicinal properties. We believe that consumers are deeply concerned about the management and cost of their health care and the expensive, chemical-based prescription drug approach predominant in modern medicine. We believe that this concern will increase the demand for bioscience health products because natural products are considered to be effective against many ailments and are more accessible than prescription medications. The global market for herbal products is currently estimated to be $62 billion and the World Health Organization has estimated that the global market for herbal products will be worth $5 trillion dollars by the year 2050. Swiss Medica, Inc., a Delaware corporation, was, prior to May 16, 2003, a holding company focused on acquiring, expanding and developing technology companies and we had no operations.
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Raghu Kilambi | CEO |
| Grant Johnson | President, Chief Operating Officer and Director |
| Bruce Fairbairn | Chief Financial Officer |
| Raghunath Kilambi | Financial Officer and Director |
| Bryson Farrill | Advisor |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| Charlie Orr | Board of Directors |
| Ronald Springer | Board of Directors |
| Sam Halim | Board of Directors |
| Organization | Position | Status |
|---|---|---|
| Swiss Medica, Inc. | CEO | Current |
| Organization | Position | Status |
|---|---|---|
| Swiss Medica, Inc. | President, Chief Operating Officer and Director | Current |
| Organization | Position | Status |
|---|---|---|
| Swiss Medica, Inc. | Chief Financial Officer | Current |
| Organization | Position | Status |
|---|---|---|
| Swiss Medica, Inc. | Financial Officer and Director | Current |
| Organization | Position | Status |
|---|---|---|
| Stargold Mines, Inc. | CEO and Director | Current |
| Swiss Medica, Inc. | Advisor | Current |
| Swiss Medica, Inc. | Chairman | Current |
| Stargold Mines, Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Wine Tasting Party | Board Member | Current |
| The Wine Club Inc. | Board Member | Current |
| Wineshop At Home | Board Member | Current |
| Swiss Medica, Inc. | Board of Directors | Current |
| Wine Tasting | Board Member | Current |
| Wine Gifts and Wine Jobs | Board Member | Current |
| Shaklee Corporation | CEO | Former |
| Shaklee Corporation | President | Former |
| Direct Selling Association | Chairman | Former |
| Provident Mutual Life Insurance Company | Director | Former |
| Herbalife Ltd. | Board of Directors | Former |
| University of Connecticut | MBA | Former |
| Wesleyan University | BA | Former |
Ronald Springer has served as a Director since May 2003. Mr. Springer has been the President and CEO of General Cosmetics Corporation since 1993. Prior to building General Cosmetics, he founded several other companies, including Heaven from Earth Corp., Ceo-Capital Corp, Global Capital Security Inc., Limardo Productions, ISB Overseas GmbH and Doitsu Shinpo. He also held positions at Esarco LTD. and Hynolds Ltd. No individual on our Board of Directors possesses all of the attributes of an audit committee financial expert and no one on our Board of Directors is deemed to be an audit committee financial expert. In forming our Board of Directors, we sought out individuals who would be able to guide our operations based on their business experience, both past and present, or their education. Our business model is not complex and our accounting issues are straightforward. Responsibility for our operations is centralized within management, which is comprised of four people. We rely on the assistance of others, such as our accountant, to help us with the preparation of our financial information. We recognize that having a person who possesses all of the attributes of an audit committee financial expert would be a valuable addition to our Board of Directors, however, we are not, at this time, able to compensate such a person therefore, we may find it difficult to attract such a candidate.
| Organization | Position | Status |
|---|---|---|
| Swiss Medica, Inc. | Board of Directors | Current |
Sam Halim has served as a Director since February 20, 2006. Mr. Halim is a trained physician and has over 15 years of business experience in the healthcare, financial services and real estate industries. Mr. Halim founded, acquired and managed Pinnacle Healthcare Technologies a company that operated multiple medical service facilities in Florida, which he sold in February 2002. Mr. Halim has served as an advisory member of GPE, Inc., a company that offers marketing and consulting services to technology and financial institutional service providers. Mr. Halim recently launched North American Physicians Inc. to distribute Swiss Medica's OTC products to the healthcare industry. Mr. Halim studied at University of Cairo Medical School (in association with University of London), New Jersey School of Osteopathic Medicine and Columbia University.
| Organization | Position | Status |
|---|---|---|
| Swiss Medica, Inc. | Board of Directors | Current |
| Volume | 18,500 |
| Shares Outstanding | 168.5M |
| Market Cap | 168.5K |
| Year High | 0.019 |
| Year Low | 0.00010 |
| Earnings Per Share | 0.00 |
| P/E Ratio | N/A |
| Dividend | 0.00 |
| Yield | 0.00 |
Industry Transcripts by Seeking Alpha
-
Neogen Corporation F2Q10 (Qtr End11/30/09) Earnings Call Transcript
on Dec 18, 2009about NEOG
-
Schiff Nutrition International, Inc. F2Q10 (Qtr End 11/30/09) Earnings Call Transcript
on Dec 17, 2009about WNI
-
Martek Biosciences Corporation F4Q09 (Qtr End 10/31/09) Earnings Call Transcript
on Dec 16, 2009about MATK
-
Peregrine Pharmaceuticals Inc. F2Q10 (Qtr End 31/10/09) Earnings Call Transcript
on Dec 10, 2009about PPHM
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone 3 votes
- VeriChip TV Ad Confirms Critics' Fears: They Want Everyone Implanted 3 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes


